TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05896293: Kisspeptin Administration Subcutaneously to Patients With IHH

Sponsor: Stephanie B. Seminara, MD · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 36 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT05896293 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05896293 Rescue Dossier →